netFormulary Northern Lincolnshire NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

NHS England - The Cancer Drugs Fund

 

Please refer to the North East Yorkshire and Humber Clinical Alliance for full cancer guidelines and chemotherapy regimens.

North East Yorkshire and Humber Clinical Alliance

 Details...
08.02.04  Expand sub section  Other immunomodulating drugs
Atezolizumab  ((Tecentriq®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Concentrate for solution for infusion 

 
Link  NICE TA492:Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520:Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584:Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
   
Controlled Drug Avelumab  ((Bavencio®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Concentrate for solution for infusion

 
Link  NICE TA 517:Avelumab for treating metastatic Merkel cell carcinoma
   
Axicabtagene ciloleuce ((Yescarta®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
 
Link  NICE TA 559:Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
   
Daratumumab ( (Darzalex®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Solution for infusion

 
Link  MHRA Drug safety update:Daratumumab (Darzalex¥): risk of reactivation of hepatitis B virus
Link  NICE TA 510:Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573:Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
Dimethyl fumarate (Tecfidera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
CCG
 
Link  NICE TA320: Dimethyl fumarate for multiple sclerosis
   
Dinutuximab  ((Qarziba®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
 
Link  NICE TA538:Dinutuximab beta for treating neuroblastoma
   
Durvalumab  ( (Imfinzi® ))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

concentrate for solution for infusion

 
Link  NICE TA578:Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
   
Fingolimod
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
   
Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) ((Kymriah®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
 
Link  NICE TA554:Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Link  NICE TA567:Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
   
Lenalidomide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Capsule

 
Link  MHRA Safety Update: Lenalidomide (Revlimid¥): update on risk of second primary malignancy
Link  MHRA Safety Update: Lenalidomide: risk of thrombosis and thromboembolism
Link  MHRA Safety Update:Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions
Link  NICE TA322:Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Link  NICE TA505:Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Link  NICE TA586:Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Link  NICE TA587:Lenalidomide plus dexamethasone for previously untreated multiple myeloma
   
Niraparib ((Zejula®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Capsule

 
Link  NICE TA528:Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
   
Nivolumab (Opdivo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
 
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Link  NICE TA558:Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Link  NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
   
Olaparib (Lynparza®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA381: Olaparib guidance
   
Osimertinib (Tagrisso)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
   
Pemrolizumab (Keytruda®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Infusion

 
Link   NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  MHRA Drug Safety Update: reports of organ transplant rejection - July 2017
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA570: Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
   
Pomalidomide (Imnovid®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
 
Link  MHRA Safety Update:Pomalidomide (Imnovid): risk of hepatitis B reactivation
Link  MHRA Safety Update:Pomalidomide (Imnovid): risks of cardiac failure, interstitial lung disease and hepatotoxicity
Link  NICE TA388: Pomalidomide for myeloma
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
   
Talimogene laherparepvac (Imlygic®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

injection

 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Teriflunomide (Aubagio®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq
 
Link  NICE TA303: Teriflunomide for relapsing remitting MS
Link  NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
   
Thalidomide (Celgene®)
(haematology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  MHRA Alert:Thalidomide: reduced starting dose in patients older than age 75 years
Link  MHRA Safety Alert: Thalidomide: risk of arterial and venous thromboembolism
Link  MHRA Safety Alert:Thalidomide: risk of second primary malignancies
Link  NICE TA228:Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
   
08.02.04  Expand sub section  Interferon Alfa
Interferon Alfa
(IntronA)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA75: Interferon Alfa - Chronic Hepatitis C
   
Interferon Alfa (Roferon-A®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Peginterferon Alfa (Pegasys®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA300: Hepatitis C - peginterferon alfa
Link  NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Link  NICE TA96: Hepatitis B - peginterferon alfa
   
Peginterferon Alfa (ViraferonPeg®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
08.02.04  Expand sub section  Interferon beta
Interferon Beta (Avonex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Injection

 
Link  MHRA Drug Safety Alert:Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon Beta (Betaferon®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Injection

 
Link  MHRA Drug Safety Alert: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon beta (Extavia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  MHRA Drug Safety Alert:Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon Beta (Rebif®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

injection

 
Link  MHRA Drug Safety Alert: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA32: Interferon Beta for MS
   
Peginterferon Beta-1a (Plegridy®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Injection

 
   
08.02.04  Expand sub section  Interferon gamma
08.02.04  Expand sub section  Aldesleukin to top
08.02.04  Expand sub section  BCG bladder instillation
08.02.04  Expand sub section  Canakinumab
08.02.04  Expand sub section  Dimethyl fumarate
08.02.04  Expand sub section  Fingolimod
08.02.04  Expand sub section  Glatiramer acetate to top
Glatiramer Acetate (Copaxone®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

injection

 
Link  NICE CG32: Glatiramer for the treatment of MS
Link  NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
   
08.02.04  Expand sub section  Histamine
08.02.04  Expand sub section  Lenalidomide, pomalidomide, and thalidomide
08.02.04  Expand sub section  Mifamurtide
Mifamurtide (Mepact®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Intravenous Infusion

 
Link  NICE TA235: Osteosarcoma - mifamurtide: guidance
   
08.02.04  Expand sub section  Natalizumab
Natalizumab (Tysabri®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

injection

 
Link  MHRA Drug Safety Alert:Natalizumab (Tysabri¨‹): progressive multifocal leukoencephalopathy¡ªupdated advice to support early detection
Link  NICE TA127: Multiple sclerosis - natalizumab
   
08.02.04  Expand sub section  Teriflunomide to top
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Green -Medicines suitable for routine use within primary care and Secondary care Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies  

Amber

Amber- Medicines suitable to be prescribed in primary care after specialist /Consultant recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust Medicines and Therapeutic Committee and approved by the Area Prescribing Committee.   

Red

Red-Hospital initiation and continuation only  

Amber Shared Care Protocol

AMBER SHARE CARE PROTOCOL- Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised  

Blue

To be supplied from the appropriate commissioned provider.   

Green 2

GREEN 2- to be prescribed by primary care only   

Grey

GREY- NON FORMULARY (As agreed by Area Prescribing Committee)  

netFormulary